Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP5 | P51878 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1124030 | 0.84 | MAPT (0.45) | GAAHTTLMNAALDH1A1NPSR1 | |
| SCHEMBL13596152 | 0.82 | SIGMAR1 (0.54) | CASP1CASP5GAASIGMAR1HTT | |
| SCHEMBL1124029 | 0.81 | CASP1 (0.61) | CASP1CASP5GAAHTTLMNA | |
| SCHEMBL8095257 | 0.81 | ACHE (0.51) | CASP1CASP5DRD4SIGMAR1HTT | |
| SCHEMBL6791357 | 0.79 | SIGMAR1 (0.45) | CASP1CASP5GAASIGMAR1HTT | |
| SCHEMBL6789057 | 0.79 | LMNA (0.51) | CASP1CASP5GAASIGMAR1LMNA | |
| SCHEMBL6784851 | 0.79 | CASP1 (0.46) | CASP1CASP5GAAHTTLMNA | |
| SCHEMBL6790642 | 0.79 | LMNA (0.47) | CASP1CASP5GAANCF1HTT | |
| SCHEMBL3246107 | 0.79 | CASP1 (0.44) | CASP1CASP5GAADRD4SIGMAR1 | |
| SCHEMBL6795876 | 0.79 | MAPT (0.51) | CASP1CASP5GAALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2140864-A2 | Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| EP-2140862-A2 | Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | BLACKBURN THOMAS P | 2009-12-24 | — | — | US | disclosed |
| US-7465750-B2 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (US) | 2008-12-16 | — | — | US | disclosed |
| US-20070259942-A1 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | BLACKBURN THOMAS P | 2007-11-08 | — | — | US | disclosed |
| US-7220775-B2 | Compound useful for the treatment of neuropathic pain | H. LUNDBECK A/S (DK) | 2007-05-22 | — | — | US | disclosed |
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | H. LUNDBECK A/S (DK) | 2004-06-10 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | CASP1 4531/4885CASP5 4051/4885GAA 546/4885 |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | CASP1 4531/4885CASP5 4051/4885GAA 546/4885 |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | GALR3, GALR2, GALR1 | CASP1 3932/4885CASP5 3929/4885GAA 521/4885 |
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | GALR3, GALR2, GALR1 | CASP1 4419/4885CASP5 3882/4885GAA 501/4885 |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | GALR3, GALR2, GALR1 | CASP1 4178/4885CASP5 3684/4885GAA 438/4885 |
| US-20070259942-A1 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | CASP1 4514/4885CASP5 3964/4885GAA 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.